The likelihood that the MGMT gene promoter is methylated was greater in tumor tissue compared with control samples (OR = 4.43, 95% CI: 2.85–6.89), indicating that NSCLC frequently has MGMT gene promoter methylation. This evidence concerns the gene MGMT and neoplasm.